Is MLAB or CDXS more profitable?

Mesa Laboratories has a net margin of 1.92% compared to Codexis' net margin of -39.55%. Mesa Laboratories' return on equity of 22.72% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Mesa Laboratories 1.92% 22.72% 9.82% Codexis -39.55% -74.36% -23.58%

Does the media refer more to MLAB or CDXS?

In the previous week, Mesa Laboratories had 3 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Mesa Laboratories and 1 mentions for Codexis. Codexis' average media sentiment score of 1.73 beat Mesa Laboratories' score of 0.84 indicating that Codexis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesa Laboratories 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Codexis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, CDXS or OABI?

Codexis has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $70.39M 2.27 -$43.97M -$0.34 N/A OmniAb $18.67M 33.58 -$64.78M -$0.36 N/A

Is CDXS or OABI more profitable?

Codexis has a net margin of -39.55% compared to OmniAb's net margin of -115.12%. OmniAb's return on equity of -16.59% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% OmniAb -115.12% -16.59% -14.82%

Does the media favor CDXS or OABI?

In the previous week, OmniAb had 4 more articles in the media than Codexis. MarketBeat recorded 5 mentions for OmniAb and 1 mentions for Codexis. Codexis' average media sentiment score of 1.73 beat OmniAb's score of 0.69 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive OmniAb 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, CDXS or EVO?

Codexis has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $70.39M 2.27 -$43.97M -$0.34 N/A Evotec $891.97M 0.74 -$117.12M N/A N/A

Is CDXS or EVO more profitable?

Evotec has a net margin of -26.20% compared to Codexis' net margin of -39.55%. Evotec's return on equity of -24.93% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% Evotec -26.20% -24.93% -11.35%

Does the media prefer CDXS or EVO?

In the previous week, Evotec had 5 more articles in the media than Codexis. MarketBeat recorded 6 mentions for Evotec and 1 mentions for Codexis. Codexis' average media sentiment score of 1.73 beat Evotec's score of -0.17 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Evotec 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CDXS or CTKB more profitable?

Cytek Biosciences has a net margin of -38.98% compared to Codexis' net margin of -39.55%. Cytek Biosciences' return on equity of -12.40% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% Cytek Biosciences -38.98% -12.40% -9.17%

Does the media prefer CDXS or CTKB?

In the previous week, Cytek Biosciences had 4 more articles in the media than Codexis. MarketBeat recorded 5 mentions for Cytek Biosciences and 1 mentions for Codexis. Codexis' average media sentiment score of 1.73 beat Cytek Biosciences' score of 0.95 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cytek Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNA or CDXS more profitable?

Codexis has a net margin of -39.55% compared to Ginkgo Bioworks' net margin of -259.96%. Ginkgo Bioworks' return on equity of -60.27% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -259.96% -60.27% -26.88% Codexis -39.55% -74.36% -23.58%

Does the media favor DNA or CDXS?

In the previous week, Ginkgo Bioworks had 6 more articles in the media than Codexis. MarketBeat recorded 7 mentions for Ginkgo Bioworks and 1 mentions for Codexis. Codexis' average media sentiment score of 1.73 beat Ginkgo Bioworks' score of -0.06 indicating that Codexis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Codexis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Codexis (CDXS) Competitors

$1.46 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

CDXS vs. MLAB, OABI, EVO, CTKB, and DNA

Should you buy Codexis stock or one of its competitors? Codexis's main competitors and comparable companies include Mesa Laboratories (MLAB), OmniAb (OABI), Evotec (EVO), Cytek Biosciences (CTKB), and Ginkgo Bioworks (DNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Codexis compare to Mesa Laboratories?

Mesa Laboratories (NASDAQ:MLAB) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

90.6% of Mesa Laboratories shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 2.8% of Mesa Laboratories shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mesa Laboratories presently has a consensus price target of $110.00, indicating a potential downside of 13.91%. Codexis has a consensus price target of $6.50, indicating a potential upside of 345.21%. Given Codexis' stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Mesa Laboratories has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Codexis has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

In the previous week, Mesa Laboratories had 3 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Mesa Laboratories and 1 mentions for Codexis. Codexis' average media sentiment score of 1.73 beat Mesa Laboratories' score of 0.84 indicating that Codexis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesa Laboratories	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Codexis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Mesa Laboratories has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.13M	2.87	$6.71M	$0.84	152.12
Codexis	$70.39M	2.27	-$43.97M	-$0.34	N/A

Mesa Laboratories has a net margin of 1.92% compared to Codexis' net margin of -39.55%. Mesa Laboratories' return on equity of 22.72% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	1.92%	22.72%	9.82%
Codexis	-39.55%	-74.36%	-23.58%

Summary

Mesa Laboratories beats Codexis on 10 of the 16 factors compared between the two stocks.

How does Codexis compare to OmniAb?

Codexis (NASDAQ:CDXS) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Codexis has a net margin of -39.55% compared to OmniAb's net margin of -115.12%. OmniAb's return on equity of -16.59% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
OmniAb	-115.12%	-16.59%	-14.82%

Codexis presently has a consensus price target of $6.50, suggesting a potential upside of 345.21%. OmniAb has a consensus price target of $11.00, suggesting a potential upside of 154.04%. Given Codexis' higher possible upside, equities analysts clearly believe Codexis is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, OmniAb had 4 more articles in the media than Codexis. MarketBeat recorded 5 mentions for OmniAb and 1 mentions for Codexis. Codexis' average media sentiment score of 1.73 beat OmniAb's score of 0.69 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
OmniAb	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Codexis has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.27	-$43.97M	-$0.34	N/A
OmniAb	$18.67M	33.58	-$64.78M	-$0.36	N/A

Codexis has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

78.5% of Codexis shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 3.5% of Codexis shares are owned by company insiders. Comparatively, 9.8% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Codexis beats OmniAb on 9 of the 15 factors compared between the two stocks.

How does Codexis compare to Evotec?

Codexis (NASDAQ:CDXS) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Codexis has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.27	-$43.97M	-$0.34	N/A
Evotec	$891.97M	0.74	-$117.12M	N/A	N/A

In the previous week, Evotec had 5 more articles in the media than Codexis. MarketBeat recorded 6 mentions for Evotec and 1 mentions for Codexis. Codexis' average media sentiment score of 1.73 beat Evotec's score of -0.17 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Evotec	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.5% of Codexis shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Codexis has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Evotec has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Codexis presently has a consensus price target of $6.50, indicating a potential upside of 345.21%. Evotec has a consensus price target of $3.00, indicating a potential upside of 61.29%. Given Codexis' stronger consensus rating and higher probable upside, analysts plainly believe Codexis is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evotec has a net margin of -26.20% compared to Codexis' net margin of -39.55%. Evotec's return on equity of -24.93% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Evotec	-26.20%	-24.93%	-11.35%

Summary

Codexis beats Evotec on 9 of the 14 factors compared between the two stocks.

How does Codexis compare to Cytek Biosciences?

Codexis (NASDAQ:CDXS) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Codexis has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.27	-$43.97M	-$0.34	N/A
Cytek Biosciences	$201.49M	3.03	-$66.54M	-$0.62	N/A

In the previous week, Cytek Biosciences had 4 more articles in the media than Codexis. MarketBeat recorded 5 mentions for Cytek Biosciences and 1 mentions for Codexis. Codexis' average media sentiment score of 1.73 beat Cytek Biosciences' score of 0.95 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cytek Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Codexis currently has a consensus target price of $6.50, indicating a potential upside of 345.21%. Cytek Biosciences has a consensus target price of $5.56, indicating a potential upside of 18.35%. Given Codexis' higher probable upside, analysts plainly believe Codexis is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Codexis has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

78.5% of Codexis shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 3.5% of Codexis shares are owned by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cytek Biosciences has a net margin of -38.98% compared to Codexis' net margin of -39.55%. Cytek Biosciences' return on equity of -12.40% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

Summary

Cytek Biosciences beats Codexis on 9 of the 16 factors compared between the two stocks.

How does Codexis compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 3.5% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ginkgo Bioworks has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Codexis has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market.

Codexis has lower revenue, but higher earnings than Ginkgo Bioworks. Codexis is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	2.75	-$312.76M	-$5.01	N/A
Codexis	$70.39M	2.27	-$43.97M	-$0.34	N/A

Codexis has a net margin of -39.55% compared to Ginkgo Bioworks' net margin of -259.96%. Ginkgo Bioworks' return on equity of -60.27% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Codexis	-39.55%	-74.36%	-23.58%

In the previous week, Ginkgo Bioworks had 6 more articles in the media than Codexis. MarketBeat recorded 7 mentions for Ginkgo Bioworks and 1 mentions for Codexis. Codexis' average media sentiment score of 1.73 beat Ginkgo Bioworks' score of -0.06 indicating that Codexis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Codexis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ginkgo Bioworks currently has a consensus price target of $7.00, indicating a potential upside of 0.72%. Codexis has a consensus price target of $6.50, indicating a potential upside of 345.21%. Given Codexis' stronger consensus rating and higher possible upside, analysts clearly believe Codexis is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Codexis beats Ginkgo Bioworks on 9 of the 16 factors compared between the two stocks.

Get Codexis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDXS vs. The Competition

Export

Metric	Codexis	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$159.89M	$9.93B	$7.21B	$12.89B
Dividend Yield	N/A	1.46%	2.54%	9.13%
P/E Ratio	-4.29	65.01	273.83	25.45
Price / Sales	2.27	112.09	625.07	95.00
Price / Cash	N/A	26.85	28.92	35.62
Price / Book	2.61	5.37	11.01	6.39
Net Income	-$43.97M	$56.67B	$3.49B	$358.69M
7 Day Performance	-14.12%	-0.76%	1.62%	0.22%
1 Month Performance	-0.68%	1.53%	4.42%	-0.10%
1 Year Performance	-39.67%	24.29%	24.18%	14.04%

Codexis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDXS Codexis	3.9193 of 5 stars	$1.46 flat	$6.50 +345.2%	-39.7%	$159.89M	$70.39M	N/A	250	Positive News Gap Down
MLAB Mesa Laboratories	1.2996 of 5 stars	$128.65 +1.2%	$110.00 -14.5%	+97.3%	$711.52M	$249.13M	153.16	680
OABI OmniAb	2.4918 of 5 stars	$4.61 -4.2%	$11.00 +138.6%	+153.2%	$696.41M	$38.46M	N/A	7	Gap Up
EVO Evotec	2.523 of 5 stars	$1.97 +1.0%	$3.00 +52.3%	-46.6%	$693.85M	$891.97M	N/A	4,553	Gap Up
CTKB Cytek Biosciences	2.0619 of 5 stars	$4.62 +1.1%	$5.56 +20.4%	+16.9%	$594.02M	$206.71M	N/A	500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDXS) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Codexis (CDXS) Competitors

CDXS vs. MLAB, OABI, EVO, CTKB, and DNA

How does Codexis compare to Mesa Laboratories?

Summary

How does Codexis compare to OmniAb?

Summary

How does Codexis compare to Evotec?

Summary

How does Codexis compare to Cytek Biosciences?

Summary

How does Codexis compare to Ginkgo Bioworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Codexis (CDXS) Competitors

CDXS vs. MLAB, OABI, EVO, CTKB, and DNA

How does Codexis compare to Mesa Laboratories?

Do insiders & institutionals hold more shares of MLAB or CDXS?

Do analysts prefer MLAB or CDXS?

Which has more risk and volatility, MLAB or CDXS?

Does the media refer more to MLAB or CDXS?

Which has preferable earnings & valuation, MLAB or CDXS?

Is MLAB or CDXS more profitable?

Summary

How does Codexis compare to OmniAb?

Is CDXS or OABI more profitable?

Do analysts recommend CDXS or OABI?

Does the media favor CDXS or OABI?

Which has better valuation & earnings, CDXS or OABI?

Which has more volatility and risk, CDXS or OABI?

Do insiders and institutionals have more ownership in CDXS or OABI?

Summary

How does Codexis compare to Evotec?

Which has higher valuation & earnings, CDXS or EVO?

Does the media prefer CDXS or EVO?

Do insiders and institutionals believe in CDXS or EVO?

Which has more volatility and risk, CDXS or EVO?

Do analysts recommend CDXS or EVO?

Is CDXS or EVO more profitable?

Summary

How does Codexis compare to Cytek Biosciences?

Which has better valuation & earnings, CDXS or CTKB?

Does the media prefer CDXS or CTKB?

Do analysts recommend CDXS or CTKB?

Which has more volatility & risk, CDXS or CTKB?

Do institutionals & insiders have more ownership in CDXS or CTKB?

Is CDXS or CTKB more profitable?

Summary

How does Codexis compare to Ginkgo Bioworks?

Do institutionals & insiders believe in DNA or CDXS?

Which has more volatility and risk, DNA or CDXS?

Which has better earnings & valuation, DNA or CDXS?

Is DNA or CDXS more profitable?

Does the media favor DNA or CDXS?

Do analysts prefer DNA or CDXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools